Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Vermeer, NS"'
Publikováno v:
Pharmacoepidemiology and Drug Safety, 25(3), 297-306. John Wiley & Sons Ltd.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::59d9bbbb2bfe5b6e7116c74d2905f21c
https://pure.eur.nl/en/publications/4b0adb30-6332-405b-b6a7-9e834f507819
https://pure.eur.nl/en/publications/4b0adb30-6332-405b-b6a7-9e834f507819
Autor:
Vermeer, NS, Bajorek, BV
Aim: To review and document the current utilization of pharmacotherapy for the secondary prevention of acute coronary syndromes (ACS) in patients discharged from an Australian hospital. Methods: A retrospective cross-sectional study was conducted at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______363::d8d3a4a639763717f1e8110164844736
https://hdl.handle.net/10453/17014
https://hdl.handle.net/10453/17014
Strategy in Regulatory Decision-Making for Management of Progressive Multifocal Leukoencephalopathy.
Autor:
Segec, A, Keller‐Stanislawski, B, Vermeer, NS, Macchiarulo, C, Straus, SM, Hidalgo‐Simon, A, De Bruin, ML
Publikováno v:
Clinical Pharmacology & Therapeutics; Nov2015, Vol. 98 Issue 5, p502-505, 4p
Autor:
Vermeer, NS, Straus, SMJM, Mantel‐Teeuwisse, AK, Hidalgo‐Simon, A, Egberts, ACG, Leufkens, HGM, De Bruin, ML
Publikováno v:
Clinical Pharmacology & Therapeutics; Nov2015, Vol. 98 Issue 5, p542-550, 9p
Autor:
Basak EA; Dept. of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address: e.basak@erasmusmc.nl., Vermeer NS; Dept. of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands., de Joode K; Dept. of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Hurkmans DP; Dept. of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Velthuis DEM; Dept. of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Oomen-de Hoop E; Dept. of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Schreurs MWJ; Dept. of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands., Bins S; Dept. of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Koolen SLW; Dept. of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Dept. of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands., Debets R; Dept. of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., van der Veldt AAM; Dept. of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Dept. of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands., Aerts JGJV; Dept. of Pulmonology, Erasmus University Medical Center, Rotterdam, the Netherlands., Joosse A; Dept. of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Mathijssen RHJ; Dept. of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 Oct; Vol. 174, pp. 113-120. Date of Electronic Publication: 2022 Aug 19.
Autor:
Vermeer NS; Erasmus MC, University Medical Center Rotterdam, Department of Hospital Pharmacy, Rotterdam, the Netherlands., Giezen TJ; Foundation Pharmacy for Hospitals in Haarlem, Haarlem, the Netherlands., Zastavnik S; European Medicines Agency (EMA), London, UK., Wolff-Holz E; Paul-Ehrlich-Institut (PEI), Langen, Germany., Hidalgo-Simon A; European Medicines Agency (EMA), London, UK.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2019 Apr; Vol. 105 (4), pp. 962-969. Date of Electronic Publication: 2019 Jan 11.
Autor:
Vermeer NS; Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.; Medicines Evaluation Board, Utrecht, The Netherlands., Ebbers HC; Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands., Straus SM; Medicines Evaluation Board, Utrecht, The Netherlands.; Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands., Leufkens HG; Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.; Medicines Evaluation Board, Utrecht, The Netherlands., Egberts TC; Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands., De Bruin ML; Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.; Medicines Evaluation Board, Utrecht, The Netherlands.
Publikováno v:
Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2016 Mar; Vol. 25 (3), pp. 297-306. Date of Electronic Publication: 2015 Dec 16.
Autor:
Klein K; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands. k.klein@escher-project.org.; TI Pharma Escher, Leiden, The Netherlands. k.klein@escher-project.org.; Exon Consultancy, Amsterdam, The Netherlands. k.klein@escher-project.org., Scholl JH; The Netherlands Pharmacovigilance Centre Lareb, Den Bosch, The Netherlands., Vermeer NS; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.; Medicines Evaluation Board (MEB), Utrecht, The Netherlands., Broekmans AW; TI Pharma Escher, Leiden, The Netherlands., Van Puijenbroek EP; The Netherlands Pharmacovigilance Centre Lareb, Den Bosch, The Netherlands., De Bruin ML; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands. M.L.deBruin@uu.nl.; Medicines Evaluation Board (MEB), Utrecht, The Netherlands. M.L.deBruin@uu.nl., Stolk P; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.; TI Pharma Escher, Leiden, The Netherlands.; Exon Consultancy, Amsterdam, The Netherlands.
Publikováno v:
Drug safety [Drug Saf] 2016 Feb; Vol. 39 (2), pp. 185-92.
Autor:
Vermeer NS; Utrecht University, Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology , Universiteitsweg 99, Utrecht, 3584CG , The Netherlands +31 302537324 ; +31 302539166 ; m.l.debruin@uu.nl., Spierings I, Mantel-Teeuwisse AK, Straus SM, Giezen TJ, Leufkens HG, Egberts TC, De Bruin ML
Publikováno v:
Expert opinion on drug safety [Expert Opin Drug Saf] 2015 Jan; Vol. 14 (1), pp. 63-72. Date of Electronic Publication: 2014 Nov 05.
Autor:
Vermeer NS; 1] Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands [2] Medicines Evaluation Board, Utrecht, The Netherlands., Duijnhoven RG; 1] Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands [2] Medicines Evaluation Board, Utrecht, The Netherlands., Straus SM; 1] Medicines Evaluation Board, Utrecht, The Netherlands [2] Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands., Mantel-Teeuwisse AK; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Arlett PR; European Medicines Agency, London, UK., Egberts AC; 1] Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands [2] Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands., Leufkens HG; 1] Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands [2] Medicines Evaluation Board, Utrecht, The Netherlands., De Bruin ML; 1] Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands [2] Medicines Evaluation Board, Utrecht, The Netherlands.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2014 Dec; Vol. 96 (6), pp. 723-31. Date of Electronic Publication: 2014 Sep 15.